接受一线化学免疫治疗的滤泡性淋巴瘤患者对COVID-19疫苗的免疫原性
在PETReA试验中,58例接受一线治疗的滤泡性淋巴瘤患者接种BNT162b2或ChAdOx1疫苗,比较其与149名健康对照的抗体和T细胞反应。患者抗体反应较低但T细胞反应保留;治疗期间接种V2、低基线IgA、苯达莫司汀及高/中危FLIPI-2与较低抗体反应相关。
要点
- 滤泡性淋巴瘤患者COVID-19疫苗抗体反应低于健康对照,T细胞反应保留。
- 诱导或维持治疗期间接种第二剂疫苗与较低抗体、较高T细胞反应独立相关。
- 苯达莫司汀和高/中危FLIPI-2评分是较低抗体反应的额外决定因素。
核心结论
- 滤泡性淋巴瘤患者COVID-19疫苗免疫原性受多种疾病和治疗相关因素影响,B细胞清除对抗体和T细胞反应呈现不同效应。
研究设计与样本
- PETReA试验(EudraCT 2016-004010-10)的一部分,纳入58例接受一线治疗的滤泡性淋巴瘤患者,并设149名健康对照。
- 患者接受利妥昔单抗联合苯达莫司汀或环磷酰胺为基础化疗的减瘤治疗,疫苗为BNT162b2或ChAdOx1,于治疗前、治疗中或治疗后接种。
- 采用Abbott Architect检测SARS-CoV-2刺突蛋白抗体,采用干扰素-γ ELISpot检测T细胞反应。
主要发现
- 与149名健康对照相比,滤泡性淋巴瘤患者抗体反应较低但T细胞反应保留。
- 多变量分析显示,低基线血清IgA水平和在诱导或维持治疗期间接种第二剂疫苗是较低抗体反应和较高T细胞反应的独立决定因素。
- 苯达莫司汀和高/中危FLIPI-2评分是较低抗体反应的额外决定因素。
- 基于预测变量组合,识别出若干临床场景,其二元免疫反应的估计置信度>95%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune responses to primary COVID-19 vaccination were investigated in 58 patients with follicular lymphoma (FL) as part of the PETReA trial of frontline therapy (EudraCT 2016-004010-10). COVID-19 vaccines (BNT162b2 or ChAdOx1) were administered before, during or after cytoreductive treatment comprising rituximab (depletes B cells) and either bendamustine (depletes CD4+ T cells) or cyclophosphamide-based chemotherapy. Blood samples obtained after vaccine doses 1 and 2 (V1, V2) were analysed for antibodies and T cells reactive to the SARS-CoV-2 spike protein using the Abbott Architect and interferon-gamma ELISpot assays respectively. Compared to 149 healthy controls, patients with FL exhibited lower antibody but preserved T-cell responses. Within the FL cohort, multivariable analysis identified low pre-treatment serum IgA levels and V2 administration during induction or maintenance treatment as independent determinants of lower antibody and higher T-cell responses, and bendamustine and high/intermediate FLIPI-2 score as additional determinants of a lower antibody response. Several clinical scenarios were identified where dichotomous immune responses were estimated with >95% confidence based on combinations of predictive variables. In conclusion, the immunogenicity of COVID-19 vaccines in FL patients is influenced by multiple disease- and treatment-related factors, among which B-cell depletion showed differential effects on antibody and T-cell responses.
引用
- Lim YJ, Ward V, Brown A, et al. Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy. Br J Haematol. 2024. PMID: 38867615. doi:10.1111/bjh.19562
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。